Please login to the form below

Not currently logged in
Email:
Password:

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

After Lucentis setback, Novartis trumpets data on follow-up drug

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis

Latest news

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... advance the duo into phase III in

  • Lucentis claims speedy FDA review for myopia complication Lucentis claims speedy FDA review for myopia complication

    in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.

  • NICE backs Bayer’s Eylea as first-line BRVO treatment NICE backs Bayer’s Eylea as first-line BRVO treatment

    This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

  • NICE backs Bayer's Eylea in diabetic eye condition NICE backs Bayer's Eylea in diabetic eye condition

    TheInstitute also recommends Allergan's Ozurdex in final guidance. Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema ... It also represents Eylea's third NICE recommendation,

More from news
Approximately 8 fully matching, plus 35 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics